Profile data is unavailable for this security.
About the company
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
- Revenue in SEK (TTM)0.00
- Net income in SEK-116.73m
- Incorporated1988
- Employees6.00
- LocationVivesto ABGustav III:s Boulevard 46, 5trSOLNA 169 73SwedenSWE
- Phone+46 18505440
- Fax+46 18510873
- Websitehttps://www.vivesto.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lipigon Pharmaceuticals AB | 16.41m | -12.71m | 35.15m | -- | -- | 1.64 | -- | 2.14 | -0.2459 | -0.2459 | 0.2138 | 0.1694 | 1.07 | -- | 21.49 | -- | -83.21 | -314.67 | -137.73 | -426.49 | -- | -- | -77.44 | -488.14 | -- | -- | 0.00 | -- | -- | 444.44 | 67.83 | -- | -- | -- |
| Oncozenge AB | 0.00 | -14.22m | 43.05m | -- | -- | 2.65 | -- | -- | -1.21 | -1.21 | 0.00 | 1.39 | 0.00 | -- | -- | -- | -58.23 | -- | -61.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
| Elicera Therapeutics AB | 12.85m | -19.50m | 46.15m | 2.00 | -- | 1.46 | -- | 3.59 | -0.9726 | -0.9726 | 0.6416 | 0.901 | 0.3015 | -- | 11.43 | 6,426,955.00 | -45.75 | -40.06 | -62.75 | -49.74 | -- | -- | -151.72 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
| Lipidor AB | 87.00k | -11.59m | 51.32m | -- | -- | -- | -- | 589.93 | -0.1049 | -0.1049 | 0.0008 | -0.0817 | 0.0122 | -- | 0.19 | -- | -162.65 | -59.41 | -- | -75.10 | -- | -- | -13,322.99 | -643.36 | -- | -- | -- | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
| Ziccum AB | 6.64m | -20.50m | 84.55m | 9.00 | -- | 6.45 | -- | 12.74 | -1.46 | -1.46 | 0.4721 | 0.8534 | 0.2696 | -- | 22.01 | 829,375.00 | -83.29 | -68.51 | -106.42 | -76.47 | -- | -- | -308.94 | -2,598.03 | -- | -- | 0.0516 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
| Odi Pharma AB (publ) | 14.80m | -1.67m | 105.78m | -- | -- | 30.31 | -- | 7.15 | -0.1097 | -0.1097 | 0.9727 | 0.2293 | 1.36 | 18.13 | 3.94 | -- | -15.36 | -- | -39.25 | -- | -25.26 | -- | -11.27 | -- | 1.26 | -2.31 | 0.00 | -- | -55.44 | -- | 4.67 | -- | -- | -- |
| StenoCare A/S | 6.25m | -25.60m | 110.30m | 9.00 | -- | 3.23 | -- | 17.65 | -1.13 | -1.13 | 0.2674 | 1.22 | 0.1285 | -- | 2.94 | -- | -52.62 | -28.16 | -70.34 | -35.47 | -- | -- | -409.55 | -371.06 | 1.04 | -5.56 | 0.2362 | -- | -16.30 | -- | -7.77 | -- | -- | -- |
| Isofol Medical AB (publ) | 0.00 | -31.16m | 111.12m | 4.00 | -- | 0.9838 | -- | -- | -0.1964 | -0.1964 | 0.00 | 0.6993 | 0.00 | -- | -- | 0.00 | -20.49 | -66.73 | -24.10 | -88.27 | -- | -- | -- | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
| Pila Pharma AB | 1.46m | -9.93m | 115.40m | 1.00 | -- | 17.32 | -- | 78.88 | -0.5304 | -0.5304 | 0.0767 | 0.28 | 0.1513 | -- | 6.11 | 1,463,020.00 | -102.68 | -108.88 | -122.66 | -121.45 | -127.88 | -42.67 | -678.73 | -1,577.64 | -- | -159.47 | 0.104 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 7.77m | -77.95m | 124.52m | 18.00 | -- | 1.29 | -- | 16.03 | -1.33 | -1.33 | 0.129 | 0.8696 | 0.0821 | -- | 4.87 | 298,730.80 | -82.36 | -63.54 | -113.92 | -75.88 | -132.91 | -1.94 | -1,003.55 | -524.31 | -- | -- | 0.0055 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |
| Vivesto AB | 0.00 | -116.73m | 144.20m | 6.00 | -- | 0.7615 | -- | -- | -0.219 | -0.219 | 0.00 | 0.352 | 0.00 | -- | -- | 0.00 | -44.08 | -- | -47.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | 64.80 | -- | -- | -- |
| Enorama Pharma AB | 670.00k | -42.47m | 165.74m | 5.00 | -- | 7.02 | -- | 247.38 | -1.03 | -1.03 | 0.0163 | 0.4271 | 0.0184 | 0.7583 | 0.6384 | 134,000.00 | -116.48 | -73.56 | -184.45 | -104.85 | -635.07 | 43.36 | -6,338.66 | -557.42 | 0.4626 | -605.70 | 0.02 | -- | -80.17 | -23.71 | -6.15 | -- | -- | -- |
| Lipum AB (publ) | 0.00 | -39.32m | 179.25m | 5.00 | -- | -- | -- | -- | -4.44 | -4.44 | 0.00 | -0.49 | 0.00 | -- | -- | 0.00 | -247.63 | -127.85 | -402.13 | -184.50 | -- | -- | -- | -293,228.70 | -- | -- | -- | -- | -- | -- | 2.38 | -- | -- | -- |
Data as of Jul 05 2024. Currency figures normalised to Vivesto AB's reporting currency: Swedish Krona SEK
1.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SEB Investment Management ABas of 31 May 2024 | 3.13m | 0.58% |
| Handelsbanken Fonder ABas of 31 May 2024 | 2.74m | 0.51% |
| Skandia Investment Management ABas of 30 Apr 2024 | 2.40m | 0.45% |
| FCG Fonder ABas of 31 Dec 2023 | 1.34m | 0.25% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 439.70k | 0.08% |
| Evli Fund Management Co. Ltd.as of 31 May 2024 | 28.66k | 0.01% |
More ▼
Data from 29 Mar 2024 - 31 May 2024Source: FactSet Research Systems Inc.
